Cancers (Sep 2023)

Preoperative Serum Levels of PDGF-AB, PDGF-BB, TGF-α, EGF and ANG-2 in the Diagnosis of Endometrial Cancer

  • Mateusz Kozłowski,
  • Dominika Borzyszkowska,
  • Justyna Mirko,
  • Agnieszka Turoń-Skrzypińska,
  • Katarzyna Piotrowska,
  • Aleksandra Tołoczko-Grabarek,
  • Sebastian Kwiatkowski,
  • Maciej Tarnowski,
  • Iwona Rotter,
  • Aneta Cymbaluk-Płoska

DOI
https://doi.org/10.3390/cancers15194815
Journal volume & issue
Vol. 15, no. 19
p. 4815

Abstract

Read online

(1) Background: It is relevant to find new diagnostic biomarkers for endometrial cancer. This study aimed to investigate whether PDGF-AB, PDGF-BB, TGF-α, EGF and ANG-2 could be considered new useful markers for diagnosis and survival of endometrial cancer. (2) Methods: A total of 93 women diagnosed with endometrial cancer (EC) and 66 patients with non-cancerous endometrial lesions (NCEL) were included in this study. (3) Results: Median serum levels of PDGF-AB, PDGF-BB, TGF-α, EGF and ANG-2 were significantly higher in the EC group compared to the NCEL group (for PDGF-AB, PDGF-BB, TGF-α and ANG-2, p = 0.0000; for EGF, p = 0.0186). The cut-off level of PDGF-AB was set at 127.69 pg/mL with a sensitivity of 87.1% and a specificity of 66.67% (AUC = 0.78, p p p p = 0.018472). The cut-off level of ANG-2 was set at 3120.68 pg/mL with a sensitivity of 72.04% and a specificity of 93.94% (AUC = 0.87, p < 0.000001). (4) Conlusion: It was concluded that all the proteins studied could be potential diagnostic markers in endometrial cancer.

Keywords